Chargement en cours...
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosin...
Enregistré dans:
| Publié dans: | Hepat Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Future Medicine Ltd
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6571544/ https://ncbi.nlm.nih.gov/pubmed/31244990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2019-0001 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|